About Johnson & JohnsonAfter a banner year, $JNJ can keep rising https://t.co/QprG1dYcTy @JNJNews via @reshmakapadia #Remicade— Barron's (@barronsonline) December 3, 2017
Johnson & Johnson Investor Relations
One of the Company’s key products, REMICADE ® (infliximab), is experiencing biosimilar competition, which will result in a reduction in U.S. sales of REMICADE ® .
Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
The Company faces a variety of risks associated with conducting business internationally.
Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation
No comments:
Post a Comment